Search

Displaying results 1151 - 1160 of 3599 in total
  1. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

    Mixtures: Bss Plus, ISOLYTE-S PH 7.4 PVC 500 ML(SETLI)
  2. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    Mixtures: Doss Tab
  3. Drug

    PI-166

    go.drugbank.com/drugs/DB05859
    Experimental

    PI-166 is a small organic compound with specific avidity to liver cancer cells.

  4. Drug

    Biotin

    go.drugbank.com/drugs/DB00121
    ApprovedInvestigationalNutraceutical

    A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.

    Mixtures: Virt-Pn, Virt-PNProducts: Bonogen Activator hair loss treatment, Biona-vit Controls and Prevents Hair Loss
  5. Drug

    Tea tree oil

    go.drugbank.com/drugs/DB11218
    ApprovedNutraceutical

    Tea tree oil is an essential oil derived mainly from the Australian native plant Melaleuca alternifolia via steam distillation of the of the leaves and terminal branches . It may be referred to as Melaleuca alternifolia oil. It has been ...

  6. Drug

    Cefixime

    go.drugbank.com/drugs/DB00671
    ApprovedInvestigational

    [A232920] β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately

  7. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

  8. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose.

  9. Target

    Nuclear receptor subfamily 0 group B member 1

    go.drugbank.com/bio_entities/BE0000074
    TargetHumans

    Nuclear receptor that lacks a DNA-binding domain and acts as a corepressor that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions (PubMed:12482977, PubMed

    Polypeptides: Nuclear receptor subfamily 0 group B member 1Synonyms: Nuclear receptor DAX-1
  10. Target

    Nuclear receptor subfamily 1 group D member 1

    go.drugbank.com/bio_entities/BE0009347
    TargetHumans

    Acts as a receptor for heme which stimulates its interaction with the NCOR1/HDAC3 corepressor complex, enhancing transcriptional repression. … Binds as a monomer to a response element composed of the consensus half-site motif 5'-[A/G]GGTCA-3' preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a direct repeat of the core motif spaced

    Polypeptides: Nuclear receptor subfamily 1 group D member 1